<DOC>
	<DOC>NCT00492037</DOC>
	<brief_summary>Study of efficacy &amp; safety of oral YM087 in subjects with euvolemic or hypervolemic hyponatremia</brief_summary>
	<brief_title>Study of Efficacy &amp; Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Serum Sodium 115 to &lt;130mEq/L Plasma Osmolarity &lt;290 mOsmol/kg H2O Significant renal insufficiency Serum sodium increase of â‰¥8 mEq/L over the baseline day ( Hours 0 to 12)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>hyponatremia</keyword>
	<keyword>hypervolemic</keyword>
	<keyword>euvolemic</keyword>
	<keyword>conivaptan</keyword>
</DOC>